Advertisement

Are we overtreating patients with T1a HER2+ Breast Cancer? An Analysis of the National Cancer Database

      ABSTRACT

      Introduction

      : The potential benefit of systemic therapy in patients with T1a HER2+ cancers is not well understood, and no consensus guidelines exist. We sought to investigate practice patterns of chemotherapy use in this population.

      Methods

      : From the National Cancer Database (2013-2018), we identified female patients with HER2+ cancers staged as cT1aN0 or pT1aN0 and stratified by receipt of chemotherapy. Using univariate and multivariable analyses we assessed the clinicopathologic features associated with the receipt of chemotherapy. We also compared rates of overall survival (OS).

      Results

      : Of 5,176 women with cT1aN0 HER2+ cancers, 88 (2%) received neoadjuvant chemotherapy. Younger age and hormone-receptor (HR) negative tumors were factors independently associated with receipt of neoadjuvant chemotherapy (all p<0.001). Of 11,688 women with pT1aN0 HER2+ cancers, 5,588 (48%) received adjuvant chemotherapy. Rates of use increased over the analysis period from 39% in 2013 to 53% in 2018 (p<0.001). Factors independently associated with receipt of adjuvant chemotherapy included younger age, having a poorly differentiated tumor, exhibiting lymphovascular invasion, undergoing adjuvant radiation (all p<0.001). There were no differences in OS when comparing those who did and did not receive chemotherapy in either group.

      Conclusions

      : The use of chemotherapy in patients with HER2+ T1a cancers is increasing over time and is, as expected, more common among patients with unfavorable clinicopathologic features. Since no prognostic algorithm currently exists, more prospective data is needed to understand which of these patients may derive benefit from systemic therapy and which may safely avoid the morbidity of chemotherapy.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Breast Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hanrahan EO
        • Gonzalez-Angulo AM
        • Giordano SH
        • et al.
        Overall Survival and Cause-Specific Mortality of Patients With Stage T1a,bN0M0 Breast Carcinoma.
        J Clin Oncol. 2007; 25: 4952-4960https://doi.org/10.1200/JCO.2006.08.0499
        • Welch HG
        • Prorok PC
        • O'Malley AJ
        • Kramer BS
        Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness.
        New England Journal of Medicine. 2016; 375: 1438-1447https://doi.org/10.1056/NEJMOA1600249/SUPPL_FILE/NEJMOA1600249_DISCLOSURES.PDF
        • Vaz-Luis I
        • Ottesen RA
        • Hughes ME
        • et al.
        Outcomes by Tumor Subtype and Treatment Pattern in Women With Small, Node-Negative Breast Cancer: A Multi-Institutional Study.
        Journal of Clinical Oncology. 2014; 32: 2142https://doi.org/10.1200/JCO.2013.53.1608
        • van Ramshorst MS
        • van der Heiden-van der Loo M
        • Dackus GMHE
        • Linn SC
        • Sonke GS.
        The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer.
        Breast Cancer Res Treat. 2016; 158: 361-371https://doi.org/10.1007/S10549-016-3878-9
        • Slamon D
        • Eiermann W
        • Robert N
        • et al.
        Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study.
        Cancer Research. 2009; 69 (62-62)https://doi.org/10.1158/0008-5472.SABCS-09-62
        • Joensuu H
        • Bono P
        • Kataja V
        • et al.
        Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: Final results of the FinHer trial.
        Journal of Clinical Oncology. 2009; 27: 5685-5692https://doi.org/10.1200/JCO.2008.21.4577
        • Spielmann M
        • Roché H
        • Delozier T
        • et al.
        Trastuzumab for patients with axillary-node-positive breast cancer: Results of the FNCLCC-PACS 04 trial.
        Journal of Clinical Oncology. 2009; 27: 6129-6134https://doi.org/10.1200/JCO.2009.23.0946
        • Hanrahan EO
        • Valero V
        • Gonzalez-Angulo AM
        • Hortobagyi GN.
        Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; Tla,bN0M0): A review of the literature.
        Journal of Clinical Oncology. 2006; 24: 2113-2122https://doi.org/10.1200/JCO.2005.02.8035
        • Curigliano G
        • Viale G
        • Bagnardi V
        • et al.
        Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer.
        J Clin Oncol. 2009; 27: 5693-5699https://doi.org/10.1200/JCO.2009.22.0962
        • Park YH
        • Kim ST
        • Cho EY
        • et al.
        A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (≤1 cm) invasive breast cancer: Who might be possible candidates for adjuvant treatment?.
        Breast Cancer Research and Treatment. 2010; 119: 653-661https://doi.org/10.1007/S10549-009-0665-X/TABLES/3
        • Parikh M
        • Galkin M
        • Brunson A
        • Keegan T
        • Chew HK.
        Breast cancer-specific survival in patients with HER2-positive, node-negative T1a and T1b breast cancer.
        Cancer Treat Res Commun. 2018; 16: 38-44https://doi.org/10.1016/J.CTARC.2018.06.001
        • Kelly CM
        • Pritchard KI
        • Trudeau M
        • Andreopoulou E
        • Hess K
        • Pusztai L.
        Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold?.
        Ann Oncol. 2011; 22: 2387-2393https://doi.org/10.1093/ANNONC/MDQ786
        • Boffa DJ
        • Rosen JE
        • Mallin K
        • et al.
        Using the National Cancer Database for Outcomes Research: A Review.
        JAMA Oncol. 2017; 3: 1722-1728https://doi.org/10.1001/jamaoncol.2016.6905
        • Mallin K
        • Browner A
        • Palis B
        • et al.
        Incident Cases Captured in the National Cancer Database Compared with Those in U.S. Population Based Central Cancer Registries in 2012–2014.
        Annals of Surgical Oncology. 2019; 26: 1604-1612https://doi.org/10.1245/s10434-019-07213-1
        • Wuerstlein R
        • Harbeck N.
        Neoadjuvant Therapy for HER2-positive Breast Cancer.
        Rev Recent Clin Trials. 2017; 12: 81-92https://doi.org/10.2174/1574887112666170202165049
      1. Petruolo O, Sevilimedu V, Montagna G, Le, Bs T, Morrow M, Barrio A V. How Often Does Modern Neoadjuvant Chemotherapy Downstage Patients to Breast-Conserving Surgery?Annals of Surgical Oncology. 28. doi:10.1245/s10434-020-08593-5

        • Von Minckwitz G
        • Untch M
        • Blohmer JU
        • et al.
        Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
        J Clin Oncol. 2012; 30: 1796-1804https://doi.org/10.1200/JCO.2011.38.8595
        • O'Shaughnessy J
        • Robert N
        • Annavarapu S
        • et al.
        Recurrence rates in patients with HER2+ breast cancer who achieved a pathological complete response after neoadjuvant pertuzumab plus trastuzumab followed by adjuvant trastuzumab: a real-world evidence study.
        Breast Cancer Res Treat. 2021; 187: 903-913https://doi.org/10.1007/S10549-021-06137-3
        • von Minckwitz G
        • Huang CS
        • Mano MS
        • et al.
        Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
        New England Journal of Medicine. 2019; 380: 617-628https://doi.org/10.1056/NEJMOA1814017/SUPPL_FILE/NEJMOA1814017_DATA-SHARING.PDF
        • Gianni L
        • Pienkowski T
        • Im YH
        • et al.
        Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
        The Lancet Oncology. 2012; 13: 25-32https://doi.org/10.1016/S1470-2045(11)70336-9
        • Schneeweiss A
        • Chia S
        • Hickish T
        • et al.
        Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).
        Ann Oncol. 2013; 24: 2278-2284https://doi.org/10.1093/ANNONC/MDT182
        • Al-Hilli Z
        • Boughey JC
        • Hoskin TL
        • Heins CN
        • Hieken TJ.
        Increasing Use of Neoadjuvant Treatment for T1 and T2 HER2-Positive Tumors.
        Annals of Surgical Oncology. 2015; 22: 3369-3375https://doi.org/10.1245/S10434-015-4718-6/TABLES/2
        • Zeidman M
        • Schmidt H
        • Alberty-Oller JJ
        • et al.
        Trends in neoadjuvant chemotherapy versus surgery-first in stage I HER2-positive breast cancer patients in the National Cancer DataBase (NCDB).
        Breast Cancer Research and Treatment. 2021; 187: 177-185https://doi.org/10.1007/S10549-020-06041-2/TABLES/2
      2. Abraham J, Aft R, Agnese D, et al. NCCN Guidelines Version 2.2022 Breast Cancer. Published 202AD. Accessed February 24, 2022. https://www.nccn.

        • Piccart-Gebhart MJ
        • Procter M
        • Leyland-Jones B
        • et al.
        Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer.
        New England Journal of Medicine. 2005; 353: 1659-1672https://doi.org/10.1056/NEJMOA052306/SUPPL_FILE/NEJM_PICCART_1659SA1-2.PDF
        • von Minckwitz G
        • Procter M
        • de Azambuja E
        • et al.
        Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
        New England Journal of Medicine. 2017; 377: 122-131https://doi.org/10.1056/NEJMOA1703643/SUPPL_FILE/NEJMOA1703643_DISCLOSURES.PDF
        • Tolaney SM
        • Guo H
        • Pernas S
        • et al.
        Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2–positive breast cancer.
        Journal of Clinical Oncology. 2019; 37: 1868-1875https://doi.org/10.1200/JCO.19.00066
        • Tolaney SM
        • Tayob N
        • Dang C
        • et al.
        Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial.
        Journal of Clinical Oncology. 2021; 39: 2375-2385https://doi.org/10.1200/JCO.20.03398
        • Lin H
        • Zheng H
        • Ge C
        • et al.
        The Effect of Adjuvant Treatment in Small Node-negative HER2-positive Breast Cancer: Which Subgroup Will Benefit?.
        Clinical Breast Cancer. 2020; 20: 503-510https://doi.org/10.1016/J.CLBC.2020.05.012
        • Cao L
        • Towe CW
        • Shenk R
        • Stabellini N
        • Amin AL
        • Montero AJ.
        A comparison of local therapy alone with local plus systemic therapy for stage I pT1aN0M0 HER2+ breast cancer: A National Cancer Database analysis.
        Cancer. 2022; 128: 2433-2440https://doi.org/10.1002/CNCR.34200
        • Kubo M
        • Kawai M
        • Kumamaru H
        • et al.
        A population-based recurrence risk management study of patients with pT1 node-negative HER2+ breast cancer: a National Clinical Database study.
        Breast Cancer Research and Treatment. 2019; 178: 647-656https://doi.org/10.1007/S10549-019-05413-7
        • Ali S
        • Hendry J
        • Le D
        • et al.
        Efficacy of adjuvant trastuzumab in women with HER2-positive T1a or bN0M0 breast cancer: a population-based cohort study.
        Scientific Reports 2022 12:1. 2022; 12: 1-8https://doi.org/10.1038/s41598-022-05209-8
      3. A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive.
        HER2-positive Breast Cancer - Full Text View - ClinicalTrials.gov. 2022; (Accessed July 6)
      4. ATEMPT 2.0: Adjuvant T-DM1 vs TH - Full Text View - ClinicalTrials.gov. Accessed July 6, 2022. https://clinicaltrials.gov/ct2/show/NCT04893109